Exact Sciences Stock Intrinsic Value – EXACT SCIENCES Reports Second Quarter Earnings Results for FY2023

🌥️Earnings Overview

EXACT SCIENCES ($NASDAQ:EXAS) announced their earnings for the second quarter of FY2023, which concluded on June 30 2023, on August 1 2023. Total revenue had risen by 19.3% to USD 622.1 million, while net income was USD -81.0 million, as opposed to -166.1 million in the previous fiscal year.

Stock Price

The stock opened at $97.0 and closed at $96.4, a decrease of 1.1% from the prior closing price of 97.5. The results were in line with analyst expectations, with no major surprises. These results demonstrate EXACT SCIENCES‘ continued commitment to driving innovation and improving patient outcomes. Overall, the company is pleased with its performance over the second quarter and is expecting to continue to grow in the future.

EXACT SCIENCES is well-positioned to capitalize on the growing demand for precision medicine solutions, as well as to develop new products and services. The company remains committed to providing innovative treatments and services that improve patient care outcomes and reduce costs. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Analysis – Exact Sciences Stock Intrinsic Value

At GoodWhale, we have completed an evaluation of the fundamentals of EXACT SCIENCES. Our proprietary Valuation Line has determined that the intrinsic value of EXACT SCIENCES is around $102.7. Notably, the stock is currently trading at $96.4. This presents a good opportunity for investors, since the stock is being undervalued by 6.1%. It is a fair price to buy and hold the stock for long-term gains. We recommend investing in EXACT SCIENCES at this time. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Exact Sciences reported its second quarter earnings results for FY2023 on August 1, 2023. Total revenue increased by 19.3% to USD 622.1 million, while net income was USD -81.0 million, a decrease from the prior year. Investors should consider the company’s overall performance, particularly its improvements in revenue, when evaluating the stock.

Additionally, EXACT SCIENCES has a solid balance sheet and a strong cash position, both of which could help the company survive any turbulent economic times. In terms of downside risk, investors should be aware of the potential for further weakening net income.